Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Deccan Health Care's Board met on 14th August 2025 via video conferencing and approved the standalone and consolidated unaudited financial results for the quarter ended 30th June 2025 (Q1 FY26), along with the limited review report by statutory auditors Keyur Shah & Associates. On a standalone basis, revenue from operations rose to ₹2,146.95 lakhs from ₹1,506.11 lakhs in Q1 FY25 (about 43% YoY growth), and profit after tax nearly tripled to ₹36.89 lakhs from ₹13.60 lakhs. Consolidated revenue grew to ₹2,214.02 lakhs and consolidated PAT rose to ₹23.71 lakhs from ₹11.14 lakhs a year earlier. The company also reported nil investor complaints during the quarter and disclosed that it issued 3,23,667 equity shares on warrant conversion while forfeiting ₹75 lakhs from warrants that lapsed after the 18-month exercise period. Director Mohak Gupta was authorised to sign the results.
Strong double-digit revenue growth and a near-doubling of standalone PAT signal a healthy quarter for shareholders, though the consolidated PAT growth is more modest due to subsidiary-level performance. The warrant conversion improves liquidity while the forfeiture of lapsed warrants boosts other income with no dilution risk.